Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
MIAMI, Jan. 12, 2022 — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain...
Read More













